Inicio › Cáncer de mama triple negativo › Texas › San Antonio
Ensayos clínicos de Cáncer de mama triple negativo en San Antonio, TX
23 estudios para Cáncer de mama triple negativo buscan participantes en centros de San Antonio y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutandoFase 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
ReclutandoFase 1/2
- NEXT Oncology, San Antonio
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
ReclutandoFase 3
- Texas Oncology - San Antonio ( Site 8001), San Antonio
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
ReclutandoFase 3
- Mays Cancer Center ( Site 0122), San Antonio
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
ReclutandoFase 3
- Texas Oncology - San Antonio ( Site 8004), San Antonio
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- NEXT Oncology, San Antonio
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
ReclutandoFase 1/2
- NEXT Oncology - San Antonio, San Antonio
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
ReclutandoFase 3
- Texas Oncology, San Antonio
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
ReclutandoFase 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
ReclutandoFase 1
- START-San Antonio, San Antonio
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Research Site, San Antonio
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
ReclutandoFase 1
- Normunity Investigational Site, San Antonio
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- START San Antonio, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Clinical Trial Site, San Antonio
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
ReclutandoFase 1
- NEXT Virginia, LLC, San Antonio
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
ReclutandoFase 1
- START San Antonio, San Antonio
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
ReclutandoFase 1
- NEXT Oncology /ID# 243007, San Antonio
- South Texas Accelerated Research Therapeutics (START) /ID# 276268, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
ReclutandoFase 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
ReclutandoFase 1
- NEXT Oncology, San Antonio
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ReclutandoFase 1
- NEXT Oncology, San Antonio
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
ReclutandoFase 1
- Dren Investigational Site, San Antonio
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
ReclutandoFase 2
- Texas Oncology PA (San Antonio), San Antonio
Ensayos de Cáncer de mama triple negativo en otras ciudades
- Houston, TX42 estudios
- New York City, NY31 estudios
- Nashville, TN28 estudios
- Los Angeles, CA27 estudios
- Boston, MA26 estudios
- St. Louis, MO21 estudios
- Arlington, VA20 estudios
- Atlanta, GA20 estudios
- Dallas, TX18 estudios
- Chicago, IL16 estudios
- Columbus, OH16 estudios
- Grand Rapids, MI15 estudios
Otros estudios en San Antonio
- Cáncer de pulmón de células no pequeñas59 estudios
- Cáncer de seno47 estudios
- Cáncer del colon y del recto46 estudios
- Cáncer metastásico44 estudios
- Cáncer (todos los tipos)41 estudios
- Obesidad40 estudios
- Diabetes tipo 237 estudios
- Sobrepeso34 estudios
- Cáncer de ovario31 estudios
- Cáncer de páncreas31 estudios
- Cáncer de próstata28 estudios
- Cáncer de endometrio27 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.